| 摘要 |
PCT No. PCT/EP93/03563 Sec. 371 Date Jun. 20, 1995 Sec. 102(e) Date Jun. 20, 1995 PCT Filed Dec. 14, 1993 PCT Pub. No. WO94/14770 PCT Pub. Date Jul. 7, 1994A compound of structure (I), in which A1 is O, S(O)n in which n is 0, 1 or 2, NR, CH2, or CH(OH); A2 is a bond or CH2; or A1A2 is CH=CH; R is hydrogen or C1-4alkyl; R1 is an optionally substituted 6- to 10-membered aryl or heteroaryl ring; suitably R1 is an optionally substituted 6- 10-membered aryl ring such as phenyl or naphthyl; suitably R1 is optionally substituted 6- to 10-membered heteroaryl ring, containing from 1 to 4 nitrogen atoms; R2 is hydrogen, halogen, C1-4alkyl, CN, NO2 or CF3; R3 is C(R4)(R5)CH2NR6R7, -CH=NNHC(NH)NH2 or a; R4 and R5 are independently hydrogen or C1-4alkyl; R6 and R7 are the same or different and are each hydrogen or C1-4alkyl or together with the nitrogen atom to which they are attached form a ring; R8 is hydrogen, C1-4alkyl, or C3-6alkenyl; the dotted lines represent an optional bond; and q and m are independently 1 or 2; and pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds are 5-HT1-like agonists (or partial agonists) and as such are expected to have utility in medicine in the treatment and/or prophylaxis of migraine, and other conditions associated with cephalic pain, such as cluster headache, headache associated with vascular disorders and other neuralgia. They are also expected to have utility in the treatment of prophylaxis of portal hypertension. <IMAGE> (I) <IMAGE> (a)
|
